{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:41:07Z","timestamp":1793410867500,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Eli Lilly Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.schres.2010.04.001","type":"journal-article","created":{"date-parts":[[2010,5,11]],"date-time":"2010-05-11T07:44:44Z","timestamp":1273563884000},"page":"204-209","source":"Crossref","is-referenced-by-count":30,"title":["Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study"],"prefix":"10.1016","volume":"120","author":[{"given":"Robert C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Lindenmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Viviano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cornwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumathi","family":"Vaidhyanathaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santica","family":"Marcovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2010.04.001_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2010.04.001_bib2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/00002512-200320120-00003","article-title":"Effects of olanzapine on lipid abnormal ties in elderly psychotic patients","volume":"20","author":"Barak","year":"2003","journal-title":"Drugs and Aging"},{"key":"10.1016\/j.schres.2010.04.001_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosissup.2008.05.003","article-title":"Are we ready for a prospective study to investigate the role of chylomicrons in cardiovascular disease?","volume":"Supplements 9","author":"Cohn","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.schres.2010.04.001_bib5","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2010.04.001_bib6","first-page":"1","article-title":"The first- and second-generation antipsychotic drugs affect ADP-induce plantlet aggregation","author":"Dietrich-Muszalska","year":"2009","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1016\/j.schres.2010.04.001_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.163.9.1077","article-title":"Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease","volume":"163","author":"Eberly","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.schres.2010.04.001_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2010.04.001_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.jcp.0000227705.56870.06","article-title":"Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics","volume":"26","author":"Hardy","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.schres.2010.04.001_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.schres.2008.10.020","article-title":"Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone","volume":"107","author":"Kelly","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.schres.2010.04.001_bib11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.ejcn.1602749","article-title":"Methodology for studying postprandial lipid metabolism","volume":"61","author":"Lairon","year":"2007","journal-title":"European Journal of Clinical Nutrition"},{"key":"10.1016\/j.schres.2010.04.001_bib12","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.schres.2010.04.001_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patient with schizophrenia treated with typical and atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.schres.2010.04.001_bib14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.4088\/JCP.08m04740yel","article-title":"Outcome evaluation of a structured educational wellness program in patients with severe mental illness","volume":"70","author":"Lindenmayer","year":"2009","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2010.04.001_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.schres.2010.04.001_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","article-title":"The effects of antipsychotic therapy on serum lipids: a comprehensive review","volume":"70","author":"Meyer","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.schres.2010.04.001_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01317.x","article-title":"The metabolic syndrome and schizophrenia","volume":"119","author":"Meyer","year":"2009","journal-title":"Acta Psychiatrica Scand."},{"issue":"Suppl1","key":"10.1016\/j.schres.2010.04.001_bib18","first-page":"1","article-title":"Second -generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2010.04.001_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4088\/JCP.08m04132","article-title":"A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone","volume":"70","author":"Newcomer","year":"2009","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2010.04.001_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2010.04.001_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/138945009787846434","article-title":"Nonfasting hyperlipidemia and cardiovascular disease","volume":"10","author":"Nordestgaard","year":"2009","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.schres.2010.04.001_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S1461145705005110","article-title":"Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients","volume":"8","author":"Smith","year":"2005","journal-title":"Int J Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2010.04.001_bib23","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","article-title":"Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study","volume":"70","author":"Smith","year":"2009","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2010.04.001_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk?","volume":"119","author":"Stahl","year":"2009","journal-title":"Acta Psychiatrica Scandinavia"},{"key":"10.1016\/j.schres.2010.04.001_bib25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FN11study)","volume":"374","author":"Tilhonen","year":"2009","journal-title":"Lancet"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996410012545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996410012545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T02:24:19Z","timestamp":1544495059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996410012545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":24,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0920996410012545"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2010.04.001","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}